Drug intelligence / Profile preview

NIP292

Development stage: Phase 1
Lead developer: Jiangzhong Pharmaceutical Group
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

NIP292 is an investigational small molecule drug developed for the treatment of idiopathic pulmonary fibrosis (IPF). It is believed to act through multiple mechanisms including anti-inflammatory and anti-fibrotic effects, vasodilation (expansion of blood vessels), and repair of vascular endothelial damage. The drug functions as a Rho-associated kinase (ROCK) inhibitor. Clinical development has included Phase 1 studies evaluating safety and tolerability in healthy adult subjects[1][3][5].

Other names: 4-fluoro-5-((6-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)sulfonyl)isoquinoline

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on NIP292.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIP292.

Explore the full profile